Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2017

View Archived Issues

Pfizer begins first-in-human study of PF-06730512

Bird Rock Bio completes phase I study of namacizumab

Synereca Pharmaceuticals develops colistin potentiators for resistant Gram-negative infections

AbCellera Biologics enters influenza vaccine research collaboration with Sanofi Pasteur

Marina Biotech acquires Prestalia from Symplmed Pharmaceuticals

FDA approves 2-month dosing option of Alkermes' Aristada

AstraZeneca agrees to divest ex-Japanese Zomig rights to Grunenthal

NanoViricides reports promising findings for topical drug candidates for shingles

First patients in phase II study respond to encochleated amphotericin B

FDA grants fast track status to Pfizer's Vyndaqel for TTR-CM

Abiraterone acetate improves survival in men starting hormone therapy for prostate cancer

Midatech licenses Novartis' panobinostat for evaluation in brain cancers

Viking Therapeutics reports promising in vivo data on VK-2809 in NASH

Living Cell Technologies gives update on phase I/IIa study of NTCELL in Parkinson's disease

Phase II data reported for tazemetostat in synovial sarcoma

Poxel reports additional results from the phase IIb imeglimin study

Warner Babcock Institute for Green Chemistry identifies new beta-amyloid aggregation inhibitors

Oppilan Pharma patents sphingosine 1-phosphate receptor 1 agonists

Daratumumab shows promise for newly diagnosed multiple myeloma patients

RQx Pharmaceuticals, Genentech describe novel signal peptidase IB inhibitors

Araxes Pharma synthesizes new KRAS inhibitors

CIMA describes novel DNMT/EHMT2 inhibitors

Novo Nordisk receives European approval for Refixia

R-Pharm CJSC discloses new tyrosine-protein kinase JAK inhibitors

Hemophilia A gene therapy from Sangamo and Pfizer receives E.U. orphan drug designation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...